Inducer microRNAs in the glioma development: a concise review of mechanisms and insights into targeted therapy

Abstract

Gliomas represent predominant and fatal central nervous system (CNS) cancers lacking a gold standard of treatment, which need accurate prognosis, diagnosis, and intervention. Glioma accurate therapy using common traditional approaches such as surgical treatment, radiotherapy, and chemotherapy results insufficient mainly due to side effects, recurrence, and resistance. Scientific and medical challenges can be decreased considering novel therapeutic targets. The multiple and diverse role of microRNAs (miRNAs) in cellular processes has been demonstrated. The appreciation of miRNAs regulatory roles in cancer cell proliferation or growth inhibition opens new perspectives in the development of novel strategies targeting cancers. Six inducers (miRNAs) including miR-363-3P, miR720, miR-484, miR-890, miR-496, and miR-939-5p can develop into glioma cells with the potential of therapeutic targets. Therefore, the tracking of glioma stage and response to anticancer therapy is associated with various miRNAs. The objective of this review is to provide a comprehensive assessment of the role of miRNAs in glioma cancer development.

Keywords: Biomarkers; Cancer therapy; Diagnosis; Glioma; MicroRNAs.